- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Gram staining.
Displaying page 1 of 1.
EudraCT Number: 2012-003621-21 | Sponsor Protocol Number: CTBM100DDE04T | Start Date*: 2013-10-09 | |||||||||||
Sponsor Name:Charité University Hospital Berlin | |||||||||||||
Full Title: Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with v... | |||||||||||||
Medical condition: Intensive care unit patients with ventilation-associated pneumonia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022410-11 | Sponsor Protocol Number: 33606.068.10 | Start Date*: 2011-07-18 |
Sponsor Name:MUMC | ||
Full Title: Topical Diclofenac and Vitamin D3 to treat Basal Cell Carcinoma | ||
Medical condition: Basal Cell Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002508-94 | Sponsor Protocol Number: OPHT-030815 | Start Date*: 2015-10-06 | ||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||
Full Title: Effect of topical azithromycin on tear film thickness in patients with meibomian gland dysfunction – comparison to oral treatment with doxycycline | ||||||||||||||||||
Medical condition: Meibomian gland dysfunction Dry eye syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002319-41 | Sponsor Protocol Number: HULP-VIR-2014-01 | Start Date*: 2015-05-11 | |||||||||||
Sponsor Name:Ana Boto de los Bueis | |||||||||||||
Full Title: Clinical and virologic assesment of two therapeutic options: antiviral Ganciclovir 0.15% ophthalmic gel and physiologic saline solution 0.9% used in patients with acute adenoviral conjuntivitis. | |||||||||||||
Medical condition: Acute adenoviral conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003304-39 | Sponsor Protocol Number: 007 | Start Date*: 2019-01-23 | ||||||||||||||||
Sponsor Name:Morten Rasmussen | ||||||||||||||||||
Full Title: Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial | ||||||||||||||||||
Medical condition: Bowel preparation before colonoscopy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001826-28 | Sponsor Protocol Number: BL-2007-02 | Start Date*: 2007-11-28 | |||||||||||
Sponsor Name:Queen Mary University London | |||||||||||||
Full Title: A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after firrst-line chemotherapy in patients with HER1 and/or HER2 over expressing locally advanced or metastati... | |||||||||||||
Medical condition: The medical condition being investigated in this trial is locally advanced or metastatic urological cancer. The tumour must overexpress HER1 and/or HER2 gene. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004605-27 | Sponsor Protocol Number: Occhuiosecco | Start Date*: 2012-11-05 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA | |||||||||||||
Full Title: Study Prospective Randomized Controlled Double-Blind: Comparison of tear substitute (Siccafluid) and Autologous Serum in Dry Eye Disease | |||||||||||||
Medical condition: Dry eye disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004875-38 | Sponsor Protocol Number: PRIMEH&N | Start Date*: 2020-11-12 | |||||||||||||||||||||
Sponsor Name:Fondazione GONO | |||||||||||||||||||||||
Full Title: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
Medical condition: HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001372-66 | Sponsor Protocol Number: TACmono-100 | Start Date*: 2014-07-16 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study. | ||
Medical condition: kidney transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002449-19 | Sponsor Protocol Number: LBH589C2204 | Start Date*: 2008-05-08 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with... | |||||||||||||
Medical condition: metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002823-46 | Sponsor Protocol Number: LT4030-201 | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:Laboratoires THÉA; Research and Development Department | |||||||||||||
Full Title: Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous... | |||||||||||||
Medical condition: Glaucoma, ocular hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) PL (Completed) HU (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001458-24 | Sponsor Protocol Number: ALN-TTR02-011 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BG (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003076-31 | Sponsor Protocol Number: VXM01-AVE-04-INT | Start Date*: 2018-10-10 | |||||||||||
Sponsor Name:VAXIMM GmbH | |||||||||||||
Full Title: An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery. | |||||||||||||
Medical condition: Progressive glioblastoma (WHO grade IV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002761-19 | Sponsor Protocol Number: OP201 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy | |||||||||||||
Medical condition: Patients with AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001402-23 | Sponsor Protocol Number: YO28322 | Start Date*: 2012-09-07 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPL... | ||||||||||||||||||
Medical condition: GASTROESOPHAGEAL CANCER | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Temporarily Halted) IT (Completed) BE (Completed) GB (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016091-80 | Sponsor Protocol Number: TCD11418 | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/car... | |||||||||||||
Medical condition: Metastatic Triple Negative Breast Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) ES (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000419-17 | Sponsor Protocol Number: AFT-38 | Start Date*: 2017-08-25 | |||||||||||||||||||||
Sponsor Name:Alliance Foundation Trials, LLC | |||||||||||||||||||||||
Full Title: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatm... | |||||||||||||||||||||||
Medical condition: HER2 Positive Breast Cancer Estrogen Receptor Positive Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004438-93 | Sponsor Protocol Number: CT-ORZY-NPC-002 | Start Date*: 2016-05-09 | |||||||||||
Sponsor Name:Orphazyme A/S | |||||||||||||
Full Title: Arimoclomol prospective double blind, randomised, placebo-controlled study in patients diagnosed with Niemann Pick disease type C | |||||||||||||
Medical condition: Niemann Pick disease type C | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) IT (Completed) PL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002553-30 | Sponsor Protocol Number: EORTC-1745-ETF-BCG | Start Date*: 2018-11-28 | |||||||||||||||||||||||||||||||
Sponsor Name:European Organisation for research and treatment of Cancer | |||||||||||||||||||||||||||||||||
Full Title: A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cance (APPALACHES) | |||||||||||||||||||||||||||||||||
Medical condition: Localized ER+ breast cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) SE (Completed) ES (Ongoing) DE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
